RVG29-DIV3W

RVG29-DIV3W is a brain-targeted chimeric peptide developed for the treatment of Alzheimer's disease. It consists of two functional domains: RVG29, a 29-amino acid peptide derived from the rabies virus glycoprotein that acts as a ligand for the nicotinic acetylcholine receptor (nAchR) to facilitate transport across the blood-brain barrier (BBB), and DIV3W, a D-amino acid peptide that serves as a potent inhibitor of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1). By crossing the BBB and inhibiting BACE1, the compound reduces the proteolytic cleavage of amyloid precursor protein (APP), thereby decreasing the generation of amyloid-beta (Aβ) peptides and preventing the formation of neurotoxic amyloid plaques. The use of D-amino acids in the DIV3W domain enhances the peptide's stability against proteolytic degradation in vivo.

Other names

RVG29-D-IV3W peptideRVG-29-D-IV3W peptideRVG 29-D-IV3W peptide